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Abstract
Introduction: The immunohistochemical examination of somatostatin receptor (SSTR) subtypes expression in different endocrine tu-
mours, including pituitary adenomas, revealed membranous or cytoplasmic distribution of SSTR1–5. Currently used long-acting soma-
tostatin analogue octreotide prefers SSTR2 and SSTR5 subtypes. In an earlier study a positive correlation between the summarized score of
SSTR2A + SSTR2B expressions and growth hormone (GH) response to octreotide administration was found, independently of receptor
distribution within the cell. In this study we searched for the relationship between the GH inhibitory response to acute octreotide admin-
istration and SSTR2A, SSTR2B, and SSTR5 cellular localization.
Material and methods: Thirteen acromegalic patients underwent a test of acute administration of octreotide before surgery. The drop in
GH was defined as the percentage of the basal value. The pituitary adenomas from these patients were immunostained to determine the
hormonal phenotype and expression of SSTR subtypes. The subcellular distribution pattern of SSTR subtypes — membranous or cytoplas-
mic — was determined.
Results: In the majority of specimens, cytoplasmic localization of receptor subtypes was observed, although membrane or mixed cytoplasmic-
membranous localized immunopositivity also occurred. The drop in GH after octreotide administration varied between 57.1–96.7% (mean
82.1%). Among the patients with the cytoplasmic localization of SSTR5, the decrease in GH was significantly higher (92.0 ± 7.0%). A tendency
towards the higher response in patients with cytoplasmic localization of SSTR2A and 2B was also observed (86.8% and 87.0%, respectively).
Conclusions: It seems that cytoplasmic localization of SSTR5, SSTR2A, and SSTR2B is connected with enhanced GH inhibition after
octreotide administration. It is possible that this somatostatin analogue alters the localization of subtypes SSTR2A and SSTR2B through the
receptor internalization. As a consequence, the SSTR-immunopositivity in cell cytoplasm is increased. The cytoplasmic but not the mem-
branous localization is connected with the higher responsiveness to the octreotide in somatotropinomas.
(Pol J Endocrinol 2010; 61 (2): 178–181)
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Streszczenie
Wstęp: Badania immunohistochemicze ekspresji podtypów receptora somatostatynowego (SSTR1–5, somatostatin receptor 1–5) w guzach
endokrynnych wykazują ich obecność zarówno w błonie komórkowej, jak i na terenie cytoplazmy komórek guza. Szeroko stosowany
obecnie syntetyczny analog somatostatyny — oktreotyd wykazuje powinowactwo głównie do podtypów SSTR2 i SSTR5. W naszych
wcześniejszych badaniach zauważono pozytywną korelację między zsumowanym wskaźnikiem (score) nasilenia odczynu immunohisto-
chemicznego SSTR2A i 2B, a hamowaniem sekrecji hormonu wzrostu (GH, growth hormone) po podaniu oktreotydu u chorych z akrome-
galią, niezależnie od lokalizacji receptorów w komórkach guza. Obecne badania autorów pracy dotyczą ewentualnej współzależności po-
między hamowaniem GH w odpowiedzi na oktreotyd a komórkową lokalizacją SSTR2A, 2B i 5.
Materiał i metody: Zbadano 13 chorych z akromegalią, u których przed operacją wykonano krótki test z oktreotydem. W gruczolakach
przysadki określono immunohistochemicznie ich fenotyp hormonalny oraz występowanie i lokalizację podtypów SSTR.
Wyniki: W większości przypadków obserwowano cytoplazmatyczną ekspresję badanych podtypów SSTR, aczkolwiek występowała rów-
nież lokalizacja błonowa i mieszana błonowo-cytoplazmatyczna. Spadek wydzielenia GH w teście hamowania oktreotydem zawierał się
w przedziale pomiędzy 57,1–96,7% (średnio 82,1%). Największy znamienny spadek wydzielenia GH (92,0 ± 7,0%) po podaniu oktreotydu
wystąpił u pacjentów z cytoplazmatyczną lokalizacją SSTR5 w komórkach guza. Zauważono także tendencję do silniejszej odpowiedzi
u pacjentów, u których również SSTR2A i 2B miały położenie cytoplazmatyczne (odpowiednio 86,8% i 87,0%).
Wnioski: Wydaje się, że cytoplazmatyczne, a nie błonowe położenie SSTR2A, 2B i 5, jest powiązane z silniejszym hamowaniem GH
w teście z oktreotydem. Możliwe, że oktreotyd w procesie internalizacji receptora zmienia jego położenie z błonowego na cytoplazma-
tyczne i zwiększa jego immunopozytywność w cytoplazmie badanych komórek guza.
(Endokrynol Pol 2010; 61 (2): 178–181)
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Introduction
The immunohistochemical investigation of somatosta-
tin receptor subtypes (SSTR) expression in different en-
docrine tumours, including pituitary adenomas, re-
vealed membranous or cytoplasmic distribution of
SSTR1–5 within the investigated tumour cells. As the
SSTR belongs to a family of seven transmembrane do-
mains linked with the G protein receptors [1, 2], one
could conclude that only the membrane-localized im-
munostaining is compatible with the functional role of
somatostatin receptors. Earlier experience supports such
a thesis [3–5]. Therefore, some authors suggest that in
neuroendocrine tumours, only the membranes located
SSTR2 are active although the active SSTR3 and SSTR5
subtypes posses the cytoplasmic localization [6, 7]. On
the other hand, in earlier studies [8–11] we described
membranous, cytoplasmic, and mixed membranous-cy-
toplasmic distribution of SSTR1–5 in thyroid, adrenal,
and pituitary tumours as well as neuroendocrine tu-
mours, without the statement of their functional state.
There is a highly variable expression of SSTR subtypes
in these tumours. This fact may partially explain why
some of them (for instance a subgroup of somatotropino-
mas or other pituitary adenomas) do not respond to the
therapeutic action of the currently used long-acting so-
matostatin analogues: SSTR2 and SSTR5, preferring oc-
treotide and lanreotide. A significant positive correlation
between the summarized score of SSTR2A + SSTR2B
expressions and growth hormone (GH) response to oc-
treotide administration was found, independently of
receptor distribution within the cell [12]. In this study
a tendency towards a positive correlation between the
summarized score of SSTR2A + SSTR2B + SSTR3 +
SSTR5 to the octreotide treatment was also observed.
However, the interdependence of the octreotide effect
and somatostatin receptor subtype SSTR2 and SSTR5
distribution was not studied. So in the present study
we would like to take into consideration the possible
relationship between GH inhibition level to acute oct-
reotide administration and SSTR2A, SSTR2B, and SSTR5
localization in somatotropinoma cells.
Material and methods
A group of 13 acromegalic patients (9 females and
4 males, aged 23–67 years, mean age 43.4 years) was
investigated. Before surgery, all of the patients under-
went a test of acute administration of octreotide (San-
dostatin, Novartis) given subcutaneously in a dose of
200 mg. The growth hormone level was measured in the
blood serum at the time intervals 0’, 60’, 120’, and 240’
after injection. The drop in GH was defined as the per-
centage of the basal value. The pituitary adenomas
removed by transsphenoidal adenomectomy from these
patients were fixed in Bouin-Hollande fixative and par-
affin embedded. All samples were immunostained with
specific mono- and polyclonal antibodies directed to pi-
tuitary hormones or a subunits to determine the hor-
monal phenotype of the adenomas. For somatostatin
receptor subtype determination, the immunohis-
tochemical procedure was performed as previously
described [13]. The 4–5 mm paraffin sections were im-
munostained using commercially available rabbit poly-
clonal antisera raised against carboxyl-terminal frag-
ments of specific human somatostatin receptor subtypes
(GRAMSCH Laboratories, Schwabhausen, Germany).
The immunoreactive intensity for specific receptor pro-
teins was scored semiquantitatively using a descriptive
scale as follows: strong staining (+++), moderate stain-
ing (++), weak staining (+), and trace staining (±).
Subcellular distribution pattern of SSTR subtypes — mem-
branous or cytoplasmic — was also determined. Statisti-
cal analysis was performed using Statistica 8 software. The
level of statistical significance was set at p < 0.05.
Results
In all the investigated tumours the immunohistochem-
ical estimation of hormonal phenotype revealed posi-
tive immunostaining of GH. In all but one tumour, PRL
was also co-expressed. In the three adenomas, co-ex-
pression of LH was found, and another two adenomas
co-expressed TSH or free a-SU. All of the adenomas
investigated expressed the somatostatin receptor sub-
types with different intensity. Only SSTR4 did not oc-
cur in any of investigated samples. We found strong
and moderate immunostaining of SSTR2A in 9/13 ade-
nomas (69.2%). In the remaining 4 cases the reaction
was weak or weak to moderate. Somatostatin receptor
2B was expressed in the same score 9/13 (69.2%). In the
remaining 4 patients the reaction was trace, weak, or
weak to moderate. The immunopositivity of SSTR5 with
strong and moderate grade of intensity appeared in
10/12 (83.3%) of the tumours. In the two adenomas the
reaction was weak to moderate. We also determined the
immunoreaction for the remaining subtypes: SSTR1
(10/12 = 83.3%) and SSTR3 (9/12 = 75%). In the majority
of specimens cytoplasmic localization of receptor sub-
types was observed, although membrane or mixed cy-
toplasmic-membranous localized immunopositivity also
occurred. The drop in GH after the octreotide adminis-
tration varied between 57.1% and 96.7% (mean 82.1%).
Thus, all patients were “responders”. Table I presents
the percentage of GH in dependence to the cellular dis-
tribution of the investigated subtypes of SSTR: 2A, 2B,
and 5. As can be seen, the decrease in GH in response
to the octreotide is significantly higher in the case of
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patients in whom the purely cytoplasmic distribution
of SSTR5 was found. There is also a tendency towards
a higher response in patients with cytoplasmic local-
ization of SSTR2A and 2B.
Discussion
The pattern of SSTR expression in acromegaly (as esti-
mated according to the percentage frequency of appear-
ance with strong to moderate intensity of staining) was
SSTR5 = SSTR1 > SSTR3 > SSTR2A = SSTR2B. It agrees
with our earlier observations [10] in which the domi-
nance of SSTR5 and, to a lesser degree, that of SSTR1
was found in somatotropinomas. In the group of 12 pa-
tients where SSTR5 was estimated, this subtype with
cytoplasmic distribution was observed in seven patients
and with mixed membranous-cytoplasmic localization
in five patients. This membranous-cytoplasmic distri-
bution was accompanied by a lower mean level of GH
inhibition after acute octreotide administration, com-
pared with SSTR2A and SSTR2B (see Table I). On the
other hand, the cytoplasmic localization of this recep-
tor subtype revealed the strongest mean GH inhibition
in this test. A similar tendency with strongest GH inhi-
bition after acute octreotide treatment was found in
cases of SSTR2A and SSTR2B localized in the cytoplasm.
Only 3 out of 13 patients demonstrated strong or mod-
erate intensity of immunohistochemical staining of
SSTR2A with membranous or mixed membranous-cy-
toplasmic distribution. The other six specimens exhib-
ited evidently only cytoplasmic localization of SSTR2A
with this grade of intensity. This fact did not support
the view that SSTR2 subtype is the integral membra-
nous form of somatostatin receptor and the rapid tar-
geting and integration of this receptor subtype into the
cell membrane is responsible for the failure of its detec-
tion in the cytoplasm. Moreover, it seems that, as in the
case of SSTR5, only cytoplasmic SSTR2A and SSTR2B
were connected with enhanced GH inhibition after
acute octreotide treatment. Consequently, it is possible that
this somatostatin analogue alters the localization of both
subtypes 2 (2A and 2B) of somatostatin receptor through
the receptor internalization and consequently increases
the SSTR-immunopositivity in cell cytoplasm. The cyto-
plasmic localization of immunoreactive receptor proteins
may be explained in several ways. Firstly, it may be the
result of receptor internalization under the influence of
an agonist, as discussed above. Secondly, it may represent
the receptor protein de novo synthesized within the en-
doplasmic reticulum. Lastly, we cannot exclude that this
localization is an artefact produced during the fixation
procedure. Summing up, the data presented above, tak-
en together with our earlier study [12], show that the
response of GH-secreting adenoma to octreotide is linked
with both the intensity of SSTR immunostaining (which
represents the total amount of immunoreactive receptor
protein) and the SSTR cellular localization, but, paradox-
ically, the cytoplasmic and not membranous localization
is connected with higher responsiveness.
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